Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Cochlear implant changes Magteld's world
2009-11-06

The microphone is ready for Magteld Smith’s (second from the left) first radio interview after the cochlear implant was switched on by Mr Henk Wolmarans (right) of MedEl. With them are, from the left: Ms Vicki Fourie, Deaf Miss SA, Ms Eunika Smith from the SABC and Prof. Jonathan Jansen.
Photo: Leatitia Pienaar


Magteld Smith gave her first steps towards the world of the hearing when her cochlear implant was switched on in the Universitas Hospital this week.

A whole team was there to share her joy and disbelief and amazement the moment she could hear noises, voices and conversations. Among them were the Rector and Vice-Chancellor of the University of the Free State (UFS), Prof. Jonathan Jansen, and the acting dean of the Faculty of Heath Sciences at the UFS, Prof. Gert van Zyl.

“I can hear my own voice! I haven’t heard it for a long time. My wish is that every deaf child can get something like this,” she said while prodding Prof. Jansen to speak so that she can hear his voice.

Magteld is working at the university's Centre for Health Systems Research and Development and was deaf since birth. She lost her last bit of hearing due to meningitis last year. Her hearing aids could then not assist her to communicate and a cochlear implant was the only option.

A donation by the Austrian company MedEl made the implant possible. Prof. André Claassen, Head of the Department of Otorhinolaryngology at the UFS, says MedEl was also instrumental in the establishment of the implant programme at the Universitas Hospital and sponsored the first five implants at a total cost of R1 million.

Prof. Claassen says 27 implants have already been done here, but it came to an abrupt halt due to a lack of funds. Strong hearing aids are expensive and cochlear implants are even more expensive at R200 000 each. People with hearing disabilities must be identified at an early age as the brain’s ability to learn sound and voice diminishes after the age of three.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept